Stoke Therapeutics(STOK) - 2024 Q1 - Quarterly Results

EX 99.1 – In April, Company strengthened its cash position with $120.3 million in net proceeds from public follow-on offering – BEDFORD, Mass., May 6, 2024 – Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the first quarter of 2024 and provided business updates including those related to STK-001, the Company's proprietary antisense ...